Claudio V Schenone, Erdem Fadiloglu, Akihiro Hasegawa, Chrystalle Katte Carreon, Ryne A Didier, Eyal Krispin, Alireza A Shamshirsaz
Introduction Spontaneous twin anemia-polycythemia sequence complicates about 3-5% of monochorionic pregnancies. This complication is associated with severe neurological morbidity and mortality in some cases. Prenatal diagnosis relies on Doppler assessment of the middle cerebral artery peak systolic velocity. However, there is ongoing debate regarding the appropriate gestational age to initiate surveillance. Case report We present a case of stage III twin anemia-polycythemia sequence, first identified at 16 weeks of gestation, given discordant middle cerebral artery peak systolic velocity (1.8 and 0.7 MoM in the anemic and polycythemic twin, respectively. Delta MCA PSV MoM 1.1), starry sky liver appearance, discordance in echogenicity and thickness of placental territories and intermittently absent end-diastolic flow in the umbilical artery of the polycythemic twin, successfully managed with fetoscopic laser photocoagulation at 17 weeks of gestation. A cesarean delivery was performed at 31 weeks of gestation by the referring team due to concomitant fetal growth restriction with lack of interval growth, abnormal umbilical artery Dopplers, and non-reassuring fetal status. Pathology confirmed ablation of all anastomotic vessels. The hemoglobin count was within normal limits for both babies (15.9 and 14.9 g/dL), and they were deemed stable for discharge at corrected gestational ages of 37 and 38 weeks, respectively. Conclusion Middle cerebral artery peak systolic velocity Doppler surveillance starting at 16 weeks of gestation is important for early detection and timely intervention of monochorionic pregnancies complicated by early severe spontaneous twin anemia-polycythemia sequence.
{"title":"Diagnosis and Management of Spontaneous Twin Anemia-Polycythemia Sequence during Early Second-Trimester: A Case Report.","authors":"Claudio V Schenone, Erdem Fadiloglu, Akihiro Hasegawa, Chrystalle Katte Carreon, Ryne A Didier, Eyal Krispin, Alireza A Shamshirsaz","doi":"10.1159/000550459","DOIUrl":"https://doi.org/10.1159/000550459","url":null,"abstract":"<p><p>Introduction Spontaneous twin anemia-polycythemia sequence complicates about 3-5% of monochorionic pregnancies. This complication is associated with severe neurological morbidity and mortality in some cases. Prenatal diagnosis relies on Doppler assessment of the middle cerebral artery peak systolic velocity. However, there is ongoing debate regarding the appropriate gestational age to initiate surveillance. Case report We present a case of stage III twin anemia-polycythemia sequence, first identified at 16 weeks of gestation, given discordant middle cerebral artery peak systolic velocity (1.8 and 0.7 MoM in the anemic and polycythemic twin, respectively. Delta MCA PSV MoM 1.1), starry sky liver appearance, discordance in echogenicity and thickness of placental territories and intermittently absent end-diastolic flow in the umbilical artery of the polycythemic twin, successfully managed with fetoscopic laser photocoagulation at 17 weeks of gestation. A cesarean delivery was performed at 31 weeks of gestation by the referring team due to concomitant fetal growth restriction with lack of interval growth, abnormal umbilical artery Dopplers, and non-reassuring fetal status. Pathology confirmed ablation of all anastomotic vessels. The hemoglobin count was within normal limits for both babies (15.9 and 14.9 g/dL), and they were deemed stable for discharge at corrected gestational ages of 37 and 38 weeks, respectively. Conclusion Middle cerebral artery peak systolic velocity Doppler surveillance starting at 16 weeks of gestation is important for early detection and timely intervention of monochorionic pregnancies complicated by early severe spontaneous twin anemia-polycythemia sequence.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hamutal Meiri, Elisa Bevilacqua, Nadav Kugler, Tamar Michelson, Adi Sharabi-Nov, Ran Svirsky, Karl Oliver Kagan, Richard N Brown, Heidy Portillo Rodriguez, Anna Goncé, Mar Bennasar, Antoni Borrell, Julia Ponce, Annegret Geipel, Adeline Walter, Corinna Simonini, Brigitte Strizek, Tanja Lennartz, Armin Bauer, Eleonora Torcia, Federica Meli, Ron Maymon, Abraham Tsur, Kypros H Nicolaides, Yoram Louzon
While machine learning models successfully predict preeclampsia in singleton pregnancies and aspirin prophylaxis prevents preterm preeclampsia, no parallel models exist for twin pregnancies. This study developed machine learning algorithms to predict preeclampsia in twins using maternal factors and biomarkers from all three trimesters. We prospectively enrolled 596 pregnant women with twin pregnancies at 11+0 to 13+6 weeks' gestation. Machine learning models assessed the efficacy of maternal factors and biomarkers for preeclampsia prediction across all trimesters. Screening performance was evaluated using area under the receiver operating characteristic (ROC) curves. Women with first-trimester risk >1/100 received aspirin treatment (150-160 mg/day) based on twin-specific algorithms, while others received 80-100 mg/day or no treatment according to local guidelines. Sixty-seven women (11.2%) developed preeclampsia, including 40 (6.7%) with preterm preeclampsia. Key first-trimester markers included maternal factors, mean arterial pressure, cell-free fetal DNA, placental growth factor, and blood group B. Second and third-trimester predictors comprised placental growth factor, soluble fms-like tyrosine kinase-1, and mean arterial pressure. The optimal machine learning model incorporating all three trimesters achieved an area under the ROC curve of 0.97 with 91% detection rate at 10% false positive rate. Despite aspirin treatment in 257 women (43.1%), logistic regression showed no significant reduction in preeclampsia rates. These findings suggest that while multi-trimester biomarkers effectively predict preeclampsia in twins, the effect of aspirin prophylaxis in twin pregnancies has yet to be proven. An app to predict this score is available at: twin-pe.math.biu.ac.il or by contact with the corresponding author.
{"title":"Preeclampsia prediction by machine learning in twin pregnancies.","authors":"Hamutal Meiri, Elisa Bevilacqua, Nadav Kugler, Tamar Michelson, Adi Sharabi-Nov, Ran Svirsky, Karl Oliver Kagan, Richard N Brown, Heidy Portillo Rodriguez, Anna Goncé, Mar Bennasar, Antoni Borrell, Julia Ponce, Annegret Geipel, Adeline Walter, Corinna Simonini, Brigitte Strizek, Tanja Lennartz, Armin Bauer, Eleonora Torcia, Federica Meli, Ron Maymon, Abraham Tsur, Kypros H Nicolaides, Yoram Louzon","doi":"10.1159/000549223","DOIUrl":"https://doi.org/10.1159/000549223","url":null,"abstract":"<p><p>While machine learning models successfully predict preeclampsia in singleton pregnancies and aspirin prophylaxis prevents preterm preeclampsia, no parallel models exist for twin pregnancies. This study developed machine learning algorithms to predict preeclampsia in twins using maternal factors and biomarkers from all three trimesters. We prospectively enrolled 596 pregnant women with twin pregnancies at 11+0 to 13+6 weeks' gestation. Machine learning models assessed the efficacy of maternal factors and biomarkers for preeclampsia prediction across all trimesters. Screening performance was evaluated using area under the receiver operating characteristic (ROC) curves. Women with first-trimester risk >1/100 received aspirin treatment (150-160 mg/day) based on twin-specific algorithms, while others received 80-100 mg/day or no treatment according to local guidelines. Sixty-seven women (11.2%) developed preeclampsia, including 40 (6.7%) with preterm preeclampsia. Key first-trimester markers included maternal factors, mean arterial pressure, cell-free fetal DNA, placental growth factor, and blood group B. Second and third-trimester predictors comprised placental growth factor, soluble fms-like tyrosine kinase-1, and mean arterial pressure. The optimal machine learning model incorporating all three trimesters achieved an area under the ROC curve of 0.97 with 91% detection rate at 10% false positive rate. Despite aspirin treatment in 257 women (43.1%), logistic regression showed no significant reduction in preeclampsia rates. These findings suggest that while multi-trimester biomarkers effectively predict preeclampsia in twins, the effect of aspirin prophylaxis in twin pregnancies has yet to be proven. An app to predict this score is available at: twin-pe.math.biu.ac.il or by contact with the corresponding author.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":1.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lennart Van der Veeken, Isabelle Ziarko, Yada Kunpalin, Nimrah Abbasi, Johannes Keunen, Homero Flores-Mendoza, Tim Van Mieghem, Greg Ryan
Background Both a low and an increased body mass index (BMI) are risk factors for surgical complications. It is less clear whether they also affect the outcomes of fetoscopic procedures. In this manuscript we aimed to assess the effect of maternal BMI on operative and pregnancy outcomes following fetoscopic laser ablation of placental anastomoses for twin-twin transfusion syndrome (TTTS). Methods We retrospectively reviewed all patients with twin pregnancies complicated by TTTS treated with fetoscopic laser surgery at the Ontario Fetal Centre, Toronto over a 24 year period. Demographic and procedural data as well as pregnancy and delivery outcomes were prospectively collected as part of our quality control program. Patients were divided into 6 groups for BMI at the time of surgery: BMI <20, 20-24.9, 25-29.9, 30-34.9, 35-39.9 and ≥40kg/m2. Collected variables included demographics, operative characteristics, operative complications, obstetric complications, TAPS, TTTS recurrence, intrauterine (fetal) death (IUFD), gestational age (GA) at delivery and survival. Outcomes of all groups were compared to the 'normal weight' reference cohort (BMI 20-24.9kg/m2). Results Of 1,012 patients in our database, 859 were twin pregnancies treated with laser for TTTS. Pregnancy outcomes were available for 515. Of all patients, 40% were categorized as normal weight, 8% were underweight, 24% were obese and 4% had a BMI > 40kg/m2. Patients with a higher BMI had higher parity (p=0.0001), longer cervical length (p=0.008) and a significantly higher TTTS stage (p=0.0003) at the time of surgery. There were no significant differences between groups in terms of surgical or anaesthetic characteristics or perinatal complications. Patients with a higher BMI however, had a lower number of anastomoses ablated at the time of surgery (p=0.047). Conclusion BMI does not significantly affect operative or perinatal outcomes in patients undergoing fetoscopic laser ablation for severe TTTS, despite being at a higher stage at diagnosis.
{"title":"The impact of maternal body mass index on fetoscopic laser surgery for TTTS.","authors":"Lennart Van der Veeken, Isabelle Ziarko, Yada Kunpalin, Nimrah Abbasi, Johannes Keunen, Homero Flores-Mendoza, Tim Van Mieghem, Greg Ryan","doi":"10.1159/000550060","DOIUrl":"https://doi.org/10.1159/000550060","url":null,"abstract":"<p><p>Background Both a low and an increased body mass index (BMI) are risk factors for surgical complications. It is less clear whether they also affect the outcomes of fetoscopic procedures. In this manuscript we aimed to assess the effect of maternal BMI on operative and pregnancy outcomes following fetoscopic laser ablation of placental anastomoses for twin-twin transfusion syndrome (TTTS). Methods We retrospectively reviewed all patients with twin pregnancies complicated by TTTS treated with fetoscopic laser surgery at the Ontario Fetal Centre, Toronto over a 24 year period. Demographic and procedural data as well as pregnancy and delivery outcomes were prospectively collected as part of our quality control program. Patients were divided into 6 groups for BMI at the time of surgery: BMI <20, 20-24.9, 25-29.9, 30-34.9, 35-39.9 and ≥40kg/m2. Collected variables included demographics, operative characteristics, operative complications, obstetric complications, TAPS, TTTS recurrence, intrauterine (fetal) death (IUFD), gestational age (GA) at delivery and survival. Outcomes of all groups were compared to the 'normal weight' reference cohort (BMI 20-24.9kg/m2). Results Of 1,012 patients in our database, 859 were twin pregnancies treated with laser for TTTS. Pregnancy outcomes were available for 515. Of all patients, 40% were categorized as normal weight, 8% were underweight, 24% were obese and 4% had a BMI > 40kg/m2. Patients with a higher BMI had higher parity (p=0.0001), longer cervical length (p=0.008) and a significantly higher TTTS stage (p=0.0003) at the time of surgery. There were no significant differences between groups in terms of surgical or anaesthetic characteristics or perinatal complications. Patients with a higher BMI however, had a lower number of anastomoses ablated at the time of surgery (p=0.047). Conclusion BMI does not significantly affect operative or perinatal outcomes in patients undergoing fetoscopic laser ablation for severe TTTS, despite being at a higher stage at diagnosis.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":1.6,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily M Scire, Judy A Estroff, Carol E Barnewolt, Ryne A Didier, David Zurakowski, Terry L Buchmiller
Introduction: Dilated colon or rectum on fetal imaging raises concern for underlying anorectal malformation (ARM) or Hirschsprung's disease (HD).
Methods: We evaluated pregnant women referred to a dedicated fetal center between 2006 and 2024 for suspected fetal rectal/colonic dilation. Findings by ultrasound and magnetic resonance imaging were compared to neonatal outcomes. Those with a statistically significant association with postnatal distal bowel abnormality were identified by univariate analysis and used to formulate a risk score.
Results: A total of 18/47 (38.2%) patients had normal imaging. A total of 29/47 (61.7%) demonstrated persistent "prominence" (15/29) or "dilation" (14/29) of the fetal colon/rectum. Seven male fetuses with large bowel dilation/prominence were diagnosed postnatally with an imperforate anus. None had HD. Compared to the no-ARM group, ARM patients were more likely to have earlier initial referral imaging; imaging noting persistent bowel dilation/prominence; imaging with an abnormal amniotic fluid level, meconium signal, bowel echogenicity, or anal sphincter; enterolithiasis; or concern for VACTERL (all p ≤ 0.035). These 8 variables were used to create a risk score to diagnose ARM with 100% sensitivity and specificity in our cohort.
Conclusion: Fetal imaging showing a dilated colon/rectum is rarely pathologic. When targeted imaging does not reveal any features predictive of pathology, reassurance may be provided to families and providers.
{"title":"Referral for Dilated Fetal Rectum: Rarely a Pathologic Entity.","authors":"Emily M Scire, Judy A Estroff, Carol E Barnewolt, Ryne A Didier, David Zurakowski, Terry L Buchmiller","doi":"10.1159/000549791","DOIUrl":"10.1159/000549791","url":null,"abstract":"<p><strong>Introduction: </strong>Dilated colon or rectum on fetal imaging raises concern for underlying anorectal malformation (ARM) or Hirschsprung's disease (HD).</p><p><strong>Methods: </strong>We evaluated pregnant women referred to a dedicated fetal center between 2006 and 2024 for suspected fetal rectal/colonic dilation. Findings by ultrasound and magnetic resonance imaging were compared to neonatal outcomes. Those with a statistically significant association with postnatal distal bowel abnormality were identified by univariate analysis and used to formulate a risk score.</p><p><strong>Results: </strong>A total of 18/47 (38.2%) patients had normal imaging. A total of 29/47 (61.7%) demonstrated persistent \"prominence\" (15/29) or \"dilation\" (14/29) of the fetal colon/rectum. Seven male fetuses with large bowel dilation/prominence were diagnosed postnatally with an imperforate anus. None had HD. Compared to the no-ARM group, ARM patients were more likely to have earlier initial referral imaging; imaging noting persistent bowel dilation/prominence; imaging with an abnormal amniotic fluid level, meconium signal, bowel echogenicity, or anal sphincter; enterolithiasis; or concern for VACTERL (all p ≤ 0.035). These 8 variables were used to create a risk score to diagnose ARM with 100% sensitivity and specificity in our cohort.</p><p><strong>Conclusion: </strong>Fetal imaging showing a dilated colon/rectum is rarely pathologic. When targeted imaging does not reveal any features predictive of pathology, reassurance may be provided to families and providers.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nuria Martínez Sánchez, Beatriz Herrero, Elena Mansilla, Carmen Prior de Castro, María De la Calle, María Concepción Prados Sánchez, Marta Ruiz de Valvuena Maíz, José Luis Bartha, Eugenia Antolín
Introduction: Cystic fibrosis (CF) is an autosomal recessive disease associated to low survival disease into adulthood. The appearance of the cystic fibrosis transmembrane conductance regulator (CFTR) therapy has revolutionized the management and the prognosis of these patients with an improvement in the pancreatic and lung function with a much better quality of life. More women with CF are considering being mothers. Other clinical scenario is the prenatal diagnosis of fetus with CF. Three case reports have been published, suggesting that CFTR therapy during pregnancy in fetuses affected by CF might prevent prenatal meconium ileus (MI), which are the one who have a higher risk of gastrointestinal morbidity and long-term complications.
Case presentation: We present 2 cases in which the diagnosis of CF occurred during intrauterine life and treatment with CFTR therapy was administered to healthy pregnant women in order to reduce the risk MI in their fetuses. In both cases, the diagnosis suspicion was by ultrasound findings with a genetic confirmed diagnosis by amniocentesis. In the first case, the mother received the CFTR therapy during 5 weeks and MI was not developed by the newborn. In the second one, the mother received the treatment only for a week and MI could not be avoided.
Conclusion: This clinical situation has special ethical considerations, since a drug is being administered through compassionate use to a woman who does not need it. The fundamental reason is the lack of authorization for the use of these drugs in newborns but in adults. We hope that these 2 clinical cases, together with those already published, will increase the knowledge and experience of using this drug in this context helping with the management of pregnant women with fetuses affected by CF in order to reduce associated complications.
{"title":"Intrauterine Treatment in Two Fetuses Affected by Cystic Fibrosis: To Whom and Since When? Report of Cases.","authors":"Nuria Martínez Sánchez, Beatriz Herrero, Elena Mansilla, Carmen Prior de Castro, María De la Calle, María Concepción Prados Sánchez, Marta Ruiz de Valvuena Maíz, José Luis Bartha, Eugenia Antolín","doi":"10.1159/000549043","DOIUrl":"10.1159/000549043","url":null,"abstract":"<p><strong>Introduction: </strong>Cystic fibrosis (CF) is an autosomal recessive disease associated to low survival disease into adulthood. The appearance of the cystic fibrosis transmembrane conductance regulator (CFTR) therapy has revolutionized the management and the prognosis of these patients with an improvement in the pancreatic and lung function with a much better quality of life. More women with CF are considering being mothers. Other clinical scenario is the prenatal diagnosis of fetus with CF. Three case reports have been published, suggesting that CFTR therapy during pregnancy in fetuses affected by CF might prevent prenatal meconium ileus (MI), which are the one who have a higher risk of gastrointestinal morbidity and long-term complications.</p><p><strong>Case presentation: </strong>We present 2 cases in which the diagnosis of CF occurred during intrauterine life and treatment with CFTR therapy was administered to healthy pregnant women in order to reduce the risk MI in their fetuses. In both cases, the diagnosis suspicion was by ultrasound findings with a genetic confirmed diagnosis by amniocentesis. In the first case, the mother received the CFTR therapy during 5 weeks and MI was not developed by the newborn. In the second one, the mother received the treatment only for a week and MI could not be avoided.</p><p><strong>Conclusion: </strong>This clinical situation has special ethical considerations, since a drug is being administered through compassionate use to a woman who does not need it. The fundamental reason is the lack of authorization for the use of these drugs in newborns but in adults. We hope that these 2 clinical cases, together with those already published, will increase the knowledge and experience of using this drug in this context helping with the management of pregnant women with fetuses affected by CF in order to reduce associated complications.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Philip Stanic, Amelia Gavulic, Marissa Ray, Todd M Jenkins, Katherine Nicole Epstein, Beth Rymeski, Foong-Yen Lim, Laura Galganski
Introduction: Currently, risk stratification criteria and indications for early postnatal resection of high-risk congenital lung malformations (CLM) are not universally accepted. In this study, we sought to characterize prenatal risk factors and outcomes associated with early postnatal resection in prenatally diagnosed CLMs.
Methods: Retrospective cohort study of patients seen at the Fetal Care Center from January 2014 to December 2023. Categorical data were analyzed with chi-square calculations. Receiver operating characteristic curves were generated for optimal CPAM volume ratio (CVR) and imaging cutoff values associated with hydrops development and/or need for early resection.
Results: Of the 204 patients analyzed, 10.2% (21/204) patients underwent early postnatal resection. Hydropic fetuses required early resection significantly more than non-hydropic fetuses (33.3% vs. 5.0%, p < 0.001). A greater number of early resection patients had macrocystic lesions compared to non-early resection patients (76.2% vs. 12.3% p < 0.001). A maximum CVR ≥1.66 was highly predictive of early postnatal resection (AUC = 0.90; 95% CI = 0.84-0.96). An initial CVR <0.88 indicated a low likelihood of developing hydrops (negative predictive value = 98.6%).
Conclusion: Prenatally, hydrops, macrocysts, and a maximum recorded CVR ≥1.66 are associated with early postnatal resection. Hydrops development is unlikely with an initial CVR <0.88.
目前,高危先天性肺畸形(CLM)产后早期切除的风险分层标准和适应症尚未被普遍接受。在这项研究中,我们试图描述产前诊断的CLMs的产前危险因素和产后早期切除相关的结果。方法:回顾性队列研究2014年1月至2023年12月在胎儿护理中心就诊的患者。分类数据采用卡方计算进行分析。生成接受者工作特征(ROC)曲线,以获得与水肿发展和/或需要早期切除相关的最佳CVR和成像截止值。结果:在分析的204例患者中,10.2%(21/204)的患者接受了产后早期切除术。积水胎儿比非积水胎儿更需要早期切除(33.3% vs. 5.0%, p < 0.001)。与未早期切除的患者相比,早期切除的患者有更多的大囊性病变(76.2%比12.3% p < 0.001)。最大CVR≥1.66高度预测早期产后切除(AUC = 0.90; 95% CI = 0.84-0.96)。初始CVR < 0.88表明发生水肿的可能性较低(阴性预测值= 98.6%)。结论:在产前,积液、大囊肿和最大记录CVR≥1.66与产后早期切除有关。初始CVR < 0.88时不太可能发生水肿。
{"title":"Character and Frequency of Early Postnatal Resection in Prenatally Diagnosed Congenital Lung Malformations.","authors":"Philip Stanic, Amelia Gavulic, Marissa Ray, Todd M Jenkins, Katherine Nicole Epstein, Beth Rymeski, Foong-Yen Lim, Laura Galganski","doi":"10.1159/000549705","DOIUrl":"10.1159/000549705","url":null,"abstract":"<p><strong>Introduction: </strong>Currently, risk stratification criteria and indications for early postnatal resection of high-risk congenital lung malformations (CLM) are not universally accepted. In this study, we sought to characterize prenatal risk factors and outcomes associated with early postnatal resection in prenatally diagnosed CLMs.</p><p><strong>Methods: </strong>Retrospective cohort study of patients seen at the Fetal Care Center from January 2014 to December 2023. Categorical data were analyzed with chi-square calculations. Receiver operating characteristic curves were generated for optimal CPAM volume ratio (CVR) and imaging cutoff values associated with hydrops development and/or need for early resection.</p><p><strong>Results: </strong>Of the 204 patients analyzed, 10.2% (21/204) patients underwent early postnatal resection. Hydropic fetuses required early resection significantly more than non-hydropic fetuses (33.3% vs. 5.0%, p < 0.001). A greater number of early resection patients had macrocystic lesions compared to non-early resection patients (76.2% vs. 12.3% p < 0.001). A maximum CVR ≥1.66 was highly predictive of early postnatal resection (AUC = 0.90; 95% CI = 0.84-0.96). An initial CVR <0.88 indicated a low likelihood of developing hydrops (negative predictive value = 98.6%).</p><p><strong>Conclusion: </strong>Prenatally, hydrops, macrocysts, and a maximum recorded CVR ≥1.66 are associated with early postnatal resection. Hydrops development is unlikely with an initial CVR <0.88.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amelia Gavulic, Madelyn Gerken, Philip Stanic, Todd M Jenkins, Monica Wagner, Stefanie Riddle, Laura Galganski, Beth Rymeski
Objectives: This study evaluated fetal MRI lung measurements with ECMO use and survival of prenatally diagnosed CDH.
Methods: Retrospective chart review of 113 patients from 01/2012-12/2023 with prenatally diagnosed congenital diaphragmatic hernias. Lung measurements from prenatal MRIs, infant ECMO use, and survival were analyzed to determine optimal cut-off value for outcome prediction.
Results: Patients were categorized as mild (10.1%, n = 11), moderate (34.3%, n = 37), and severe (55.6%, n = 60). Mortality was 29.2% (n = 33), and 52.2% (n = 59) required ECMO. Patients undergoing FETO (n = 11) were excluded from statistical analysis. Median change in total lung volume, ipsilateral lung, and contralateral lung from early to late gestation MRI was 15.1 mL (IQR: 9.3-21.7), 1.5 mL (IQR: 0.1-3.1), and 13.4 mL (IQR: 8.1-18.34), respectively. Optimal cut-off values, sensitivity, specificity, positive predictive value, and negative predictive value were calculated for each volume parameter in terms of predicting ECMO use and mortality. Ipsilateral and contralateral lung growth below the cut-off significantly predicted ECMO use (p < 0.05). There was no significance for any cut-offs predicting mortality.
Conclusion: Lung volume growth measured by MRI in prenatally diagnosed CDH may be a useful predictor of ECMO use and mortality.
{"title":"MRI Lung Volume Prediction of ECMO and Mortality in Congenital Diaphragmatic Hernia.","authors":"Amelia Gavulic, Madelyn Gerken, Philip Stanic, Todd M Jenkins, Monica Wagner, Stefanie Riddle, Laura Galganski, Beth Rymeski","doi":"10.1159/000549792","DOIUrl":"https://doi.org/10.1159/000549792","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated fetal MRI lung measurements with ECMO use and survival of prenatally diagnosed CDH.</p><p><strong>Methods: </strong>Retrospective chart review of 113 patients from 01/2012-12/2023 with prenatally diagnosed congenital diaphragmatic hernias. Lung measurements from prenatal MRIs, infant ECMO use, and survival were analyzed to determine optimal cut-off value for outcome prediction.</p><p><strong>Results: </strong>Patients were categorized as mild (10.1%, n = 11), moderate (34.3%, n = 37), and severe (55.6%, n = 60). Mortality was 29.2% (n = 33), and 52.2% (n = 59) required ECMO. Patients undergoing FETO (n = 11) were excluded from statistical analysis. Median change in total lung volume, ipsilateral lung, and contralateral lung from early to late gestation MRI was 15.1 mL (IQR: 9.3-21.7), 1.5 mL (IQR: 0.1-3.1), and 13.4 mL (IQR: 8.1-18.34), respectively. Optimal cut-off values, sensitivity, specificity, positive predictive value, and negative predictive value were calculated for each volume parameter in terms of predicting ECMO use and mortality. Ipsilateral and contralateral lung growth below the cut-off significantly predicted ECMO use (p < 0.05). There was no significance for any cut-offs predicting mortality.</p><p><strong>Conclusion: </strong>Lung volume growth measured by MRI in prenatally diagnosed CDH may be a useful predictor of ECMO use and mortality.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-23"},"PeriodicalIF":1.6,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisabet Baldrich-Martin, Gloria Jalencas, Isabel Mazano, Cristina Lesmes-Heredia, Josep-Maria Manresa-Dominguez, Maria Iniguez-Cruz, Joan-Carles Ferreres, Viviana Beltran, Antoni Borrell
Introduction: The aim of this study was to assess the clinical utility of low-set ears (LSE) as a novel 2D-ultrasound marker for the prenatal detection of chromosomal anomalies.
Methods: A multicenter cohort study including 1,331 singleton pregnancies between 11+2 and 34+6 weeks of gestation was conducted in the two participating centers to determine the performance of LSE as an aneuploidy marker. LSE was defined as a dichotomous marker using a newly defined axial plane of the fetal head in 2D ultrasound. Intra- and interobserver variability were assessed to ensure marker reliability. Efficacy in predicting chromosomal anomalies was assessed using LSE alone or in combination with aneuploidy screening.
Results: A new axial plane of the fetal head, defined by both lenses and the cerebellum, was adopted for LSE detection. Intra-observer concordance Kappa index for LSE measurement was 1.0, and 0.82 for interobserver reliability. LSE could be assessed in 99% of the studied fetuses and was detected in 30 (2.3%) fetuses: in 19 (86%) of the 22 fetuses with chromosomal anomalies, in all cases (5/5, 100%) with other genetic anomalies, and in six (18%) of the 34 malformed fetuses without a genetic disorder. In one (3.3%) of the fetuses, LSE was not confirmed postnatally while the remaining 29 fetuses had an adverse outcome. When LSE was combined with aneuploidy screening, the detection rate of chromosomal anomalies remained the same and specificity increased from 89% to 100%.
Conclusions: Our study supports using LSE as a potential 2D-ultrasound marker for chromosomal anomaly detection. Studies with a larger sample size and in high-risk populations are warranted to prove its clinical utility before this marker can be included in prenatal screening protocols.
{"title":"Low-Set Ears: A New Marker of Fetal Chromosomal Anomalies.","authors":"Elisabet Baldrich-Martin, Gloria Jalencas, Isabel Mazano, Cristina Lesmes-Heredia, Josep-Maria Manresa-Dominguez, Maria Iniguez-Cruz, Joan-Carles Ferreres, Viviana Beltran, Antoni Borrell","doi":"10.1159/000548946","DOIUrl":"10.1159/000548946","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to assess the clinical utility of low-set ears (LSE) as a novel 2D-ultrasound marker for the prenatal detection of chromosomal anomalies.</p><p><strong>Methods: </strong>A multicenter cohort study including 1,331 singleton pregnancies between 11+2 and 34+6 weeks of gestation was conducted in the two participating centers to determine the performance of LSE as an aneuploidy marker. LSE was defined as a dichotomous marker using a newly defined axial plane of the fetal head in 2D ultrasound. Intra- and interobserver variability were assessed to ensure marker reliability. Efficacy in predicting chromosomal anomalies was assessed using LSE alone or in combination with aneuploidy screening.</p><p><strong>Results: </strong>A new axial plane of the fetal head, defined by both lenses and the cerebellum, was adopted for LSE detection. Intra-observer concordance Kappa index for LSE measurement was 1.0, and 0.82 for interobserver reliability. LSE could be assessed in 99% of the studied fetuses and was detected in 30 (2.3%) fetuses: in 19 (86%) of the 22 fetuses with chromosomal anomalies, in all cases (5/5, 100%) with other genetic anomalies, and in six (18%) of the 34 malformed fetuses without a genetic disorder. In one (3.3%) of the fetuses, LSE was not confirmed postnatally while the remaining 29 fetuses had an adverse outcome. When LSE was combined with aneuploidy screening, the detection rate of chromosomal anomalies remained the same and specificity increased from 89% to 100%.</p><p><strong>Conclusions: </strong>Our study supports using LSE as a potential 2D-ultrasound marker for chromosomal anomaly detection. Studies with a larger sample size and in high-risk populations are warranted to prove its clinical utility before this marker can be included in prenatal screening protocols.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: The clinical phenotypes associated with 1q21.1 deletion or duplication syndromes vary considerably among individuals, and the underlying mechanisms remain poorly elucidated. Moreover, data on prenatal ultrasound findings in fetuses carrying these copy number variants are still limited. This study aimed to preliminarily evaluate the association between prenatal phenotypic features and 1q21.1 deletion/duplication syndromes.
Methods: A retrospective analysis was performed on 16 cases diagnosed with 1q21.1 deletions and 13 cases with 1q21.1 duplications, employing single nucleotide polymorphism arrays (SNP-arrays).
Results: The deletion fragment sizes of the 16 deletion cases ranged from 1.30 Mb to 2.18 Mb, with the overlapping region located at 146.5 Mb to 147.5 Mb, encompassing nine OMIM genes such as ACP6, BCL9, and CHD1L. The fragment sizes of the 13 duplication cases ranged from 0.87 Mb to 3.87 Mb, with the overlapping region located at 146.5 Mb to 147.0 Mb, encompassing a total of 4 OMIM genes, namely, BCL9, CHD1L, FMO5, and PRKAB2. Among the 16 fetuses with deletions, eight exhibited ultrasound-detected abnormalities. Specifically, three fetuses had urinary tract malformations, four were diagnosed with fetal growth retardation, three displayed lateral ventricle enlargement, and one had aortic stenosis. Of the 13 fetuses with duplication, six were found to have ultrasound abnormalities, including four fetuses with cardiovascular malformations, one fetus with fetal growth retardation, one fetus with widened posterior fossa, and one fetus with widened lateral ventricle. Among the 16 fetuses identified with deletions, nine pregnancies were electively terminated, while seven pregnancies were carried to term, resulting in normal births. During follow-up, one child was diagnosed with epilepsy, and another exhibited delays in language and motor development. In the cohort of 13 fetuses with duplications, four pregnancies were terminated, and nine proceeded to term, yielding normal births. However, follow-up assessments revealed that one child experienced hearing impairment and another demonstrated speech delays.
Conclusion: This study suggests that fetuses with prenatal 1q21.1 deletions may be associated with malformations of the urinary system, whereas those with 1q21.1 duplications are likely associated with cardiac malformations. For fetuses diagnosed with 1q21.1 deletions or duplications who present with a normal phenotype prenatally, it is essential to conduct close monitoring of their neurodevelopmental trajectory postnatally.
{"title":"Prenatal Diagnosis, Ultrasound Findings, and Follow-Up Information of 1q21.1 Deletion and Duplication Syndromes: A Single-Center Case Series.","authors":"Xiaojin Luo, Xiaohang Chen, Yanli Tang, Li Liu, Jinmao Xu, Liping Wu, Yuanyuan Pei, Weiqiang Liu, Fengxiang Wei","doi":"10.1159/000549222","DOIUrl":"10.1159/000549222","url":null,"abstract":"<p><strong>Introduction: </strong>The clinical phenotypes associated with 1q21.1 deletion or duplication syndromes vary considerably among individuals, and the underlying mechanisms remain poorly elucidated. Moreover, data on prenatal ultrasound findings in fetuses carrying these copy number variants are still limited. This study aimed to preliminarily evaluate the association between prenatal phenotypic features and 1q21.1 deletion/duplication syndromes.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 16 cases diagnosed with 1q21.1 deletions and 13 cases with 1q21.1 duplications, employing single nucleotide polymorphism arrays (SNP-arrays).</p><p><strong>Results: </strong>The deletion fragment sizes of the 16 deletion cases ranged from 1.30 Mb to 2.18 Mb, with the overlapping region located at 146.5 Mb to 147.5 Mb, encompassing nine OMIM genes such as ACP6, BCL9, and CHD1L. The fragment sizes of the 13 duplication cases ranged from 0.87 Mb to 3.87 Mb, with the overlapping region located at 146.5 Mb to 147.0 Mb, encompassing a total of 4 OMIM genes, namely, BCL9, CHD1L, FMO5, and PRKAB2. Among the 16 fetuses with deletions, eight exhibited ultrasound-detected abnormalities. Specifically, three fetuses had urinary tract malformations, four were diagnosed with fetal growth retardation, three displayed lateral ventricle enlargement, and one had aortic stenosis. Of the 13 fetuses with duplication, six were found to have ultrasound abnormalities, including four fetuses with cardiovascular malformations, one fetus with fetal growth retardation, one fetus with widened posterior fossa, and one fetus with widened lateral ventricle. Among the 16 fetuses identified with deletions, nine pregnancies were electively terminated, while seven pregnancies were carried to term, resulting in normal births. During follow-up, one child was diagnosed with epilepsy, and another exhibited delays in language and motor development. In the cohort of 13 fetuses with duplications, four pregnancies were terminated, and nine proceeded to term, yielding normal births. However, follow-up assessments revealed that one child experienced hearing impairment and another demonstrated speech delays.</p><p><strong>Conclusion: </strong>This study suggests that fetuses with prenatal 1q21.1 deletions may be associated with malformations of the urinary system, whereas those with 1q21.1 duplications are likely associated with cardiac malformations. For fetuses diagnosed with 1q21.1 deletions or duplications who present with a normal phenotype prenatally, it is essential to conduct close monitoring of their neurodevelopmental trajectory postnatally.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145488286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acknowledgement to Reviewers.","authors":"","doi":"10.1159/000548998","DOIUrl":"https://doi.org/10.1159/000548998","url":null,"abstract":"","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-2"},"PeriodicalIF":1.6,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145488239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}